Dr. Alexander Kretschmer, MD, discusses the clinical interpretation and value of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result.
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
HUMC provides groundbreaking focal therapy for prostate cancer
September 13th 2023The Focal One high intensity focused ultrasound system uses precision sound waves to destroy prostate tumor tissue and spare healthy tissue, reducing the risk of side effects that would lower a patient's quality of life.
2 Clarke Drive
Cranbury, NJ 08512